,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2018', 'fs': 'Jul 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSC2A1'}, 'Id': 'a0POZ00000FSpSC2A1', 'Event_Date__c': '2018-07-30', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2018', 'Status_History__c': 'a132P000000ArUzQAK'}, 'change': None}]",Jul 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2019', 'fs': 'Jan 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSD2A1'}, 'Id': 'a0POZ00000FSpSD2A1', 'Event_Date__c': '2019-01-14', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2019', 'Status_History__c': 'a132P000000AraNQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE be deferred due to insufficient evidence for the use of fosfomycin for this indication at this time. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.</p>', 'fs': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE be deferred due to insufficient evidence for the use of fosfomycin for this indication at this time. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE</p><p><br></p><p>The Subcommittee noted that fosfomycin inhibits the first stage of intracellular bacterial wall synthesis by blocking peptidoglycan synthesis. The Subcommittee noted that fosfomycin is widely distributed in the body including to the cerebrospinal fluid, has a half-life of 1.9 to 3.9 hours and is excreted through the kidneys. </p><p><br></p><p>The Subcommittee noted that fosfomycin is supplied as a 2 g, 4 g or 8 g vial of powder for reconstitution and that it is administered by intravenous (IV) infusion. The Subcommittee noted that fosfomycin is not approved by Medsafe, however the oral formulation of fosfomycin is currently listed in the Hospital Medicines List (HML) and is undergoing registration.</p><p><br></p><p>The Subcommittee noted there is limited evidence available for fosfomycin for salvage therapy for infections caused by CRE, and noted the following publications:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/24648559"" target=""_blank"">Kaase et al. J Clin Microbiol. 2014;52:1893-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/19694767?dopt=Abstract"" target=""_blank"">Michalopoulos et al. Clin Microbiol Infect. 2010;16:184-6.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/23715037"" target=""_blank"">Pogue et al. J Antibiot (Tokyo). 2013;66:625-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/27384881"" target=""_blank"">Thaden et al. Virulence. 2017;8:403-416</a>.</p><p><br></p><p>The Subcommittee considered that the minimum inhibitory concentration (MIC) and pharmacokinetic (PK) parameters of fosfomycin need to be better understood in order to facilitate proper use of fosfomycin in salvage therapy. </p><p><br></p><p>The Subcommittee considered that fosfomycin could have a synergistic treatment effect when used with other agents and that the best use of fosfomycin may be against CRE, however, more evidence is needed to understand the agent and its optimal use. </p><p><br></p><p>The Subcommittee considered there were concerns about the rate of development of resistance to fosfomycin, seen in pre-clinical data and in real world clinical practice. </p><p><br></p><p>The Subcommittee considered that the clinical data for fosfomycin for the treatment of CRE infections is very limited and consists of very small case series, and the Subcommittee considered that is evidence base insufficient to assess the potential risks and benefits of fosfomycin for this indication. </p><p><br></p><p>The Subcommittee considered that further clinical trial data would be forthcoming for fosfomycin in the treatment of CRE infection. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.).</p>', 'fs': '<p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE</p><p><br></p><p>The Subcommittee noted that fosfomycin inhibits the first stage of intracellular bacterial wall synthesis by blocking peptidoglycan synthesis. The Subcommittee noted that fosfomycin is widely distributed in the body including to the cerebrospinal fluid, has a half-life of 1.9 to 3.9 hours and is excreted through the kidneys. </p><p><br></p><p>The Subcommittee noted that fosfomycin is supplied as a 2 g, 4 g or 8 g vial of powder for reconstitution and that it is administered by intravenous (IV) infusion. The Subcommittee noted that fosfomycin is not approved by Medsafe, however the oral formulation of fosfomycin is currently listed in the Hospital Medicines List (HML) and is undergoing registration.</p><p><br></p><p>The Subcommittee noted there is limited evidence available for fosfomycin for salvage therapy for infections caused by CRE, and noted the following publications:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/24648559"" target=""_blank"">Kaase et al. J Clin Microbiol. 2014;52:1893-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/19694767?dopt=Abstract"" target=""_blank"">Michalopoulos et al. Clin Microbiol Infect. 2010;16:184-6.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/23715037"" target=""_blank"">Pogue et al. J Antibiot (Tokyo). 2013;66:625-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/27384881"" target=""_blank"">Thaden et al. Virulence. 2017;8:403-416</a>.</p><p><br></p><p>The Subcommittee considered that the minimum inhibitory concentration (MIC) and pharmacokinetic (PK) parameters of fosfomycin need to be better understood in order to facilitate proper use of fosfomycin in salvage therapy. </p><p><br></p><p>The Subcommittee considered that fosfomycin could have a synergistic treatment effect when used with other agents and that the best use of fosfomycin may be against CRE, however, more evidence is needed to understand the agent and its optimal use. </p><p><br></p><p>The Subcommittee considered there were concerns about the rate of development of resistance to fosfomycin, seen in pre-clinical data and in real world clinical practice. </p><p><br></p><p>The Subcommittee considered that the clinical data for fosfomycin for the treatment of CRE infections is very limited and consists of very small case series, and the Subcommittee considered that is evidence base insufficient to assess the potential risks and benefits of fosfomycin for this indication. </p><p><br></p><p>The Subcommittee considered that further clinical trial data would be forthcoming for fosfomycin in the treatment of CRE infection. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.).</p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by carbapenem-resistant <i>Enterobacteriaceae</i> (CRE)</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by carbapenem-resistant <i>Enterobacteriaceae</i> (CRE)</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'fs': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSE2A1'}, 'Id': 'a0POZ00000FSpSE2A1', 'Event_Date__c': '2019-05-10', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Friday 10 May 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-record-2019-05.pdf</p>', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'May 2019', 'Published_Recommendation__c': '<p><span style=""font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> that fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE be deferred due to insufficient evidence for the use of fosfomycin for this indication at this time. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.</p>', 'Published_Application__c': '<p>The Subcommittee reviewed the following applications for salvage therapy for the treatment of multidrug-resistant organisms:</p><p><br></p><p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by carbapenem-resistant <i>Enterobacteriaceae</i> (CRE)</p><p><br></p><p>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>Fosfomycin (Fomicyt or Fosmicin) for salvage therapy for infections caused by CRE</p><p><br></p><p>The Subcommittee noted that fosfomycin inhibits the first stage of intracellular bacterial wall synthesis by blocking peptidoglycan synthesis. The Subcommittee noted that fosfomycin is widely distributed in the body including to the cerebrospinal fluid, has a half-life of 1.9 to 3.9 hours and is excreted through the kidneys. </p><p><br></p><p>The Subcommittee noted that fosfomycin is supplied as a 2 g, 4 g or 8 g vial of powder for reconstitution and that it is administered by intravenous (IV) infusion. The Subcommittee noted that fosfomycin is not approved by Medsafe, however the oral formulation of fosfomycin is currently listed in the Hospital Medicines List (HML) and is undergoing registration.</p><p><br></p><p>The Subcommittee noted there is limited evidence available for fosfomycin for salvage therapy for infections caused by CRE, and noted the following publications:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/24648559"" target=""_blank"">Kaase et al. J Clin Microbiol. 2014;52:1893-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/19694767?dopt=Abstract"" target=""_blank"">Michalopoulos et al. Clin Microbiol Infect. 2010;16:184-6.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/23715037"" target=""_blank"">Pogue et al. J Antibiot (Tokyo). 2013;66:625-7.</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/27384881"" target=""_blank"">Thaden et al. Virulence. 2017;8:403-416</a>.</p><p><br></p><p>The Subcommittee considered that the minimum inhibitory concentration (MIC) and pharmacokinetic (PK) parameters of fosfomycin need to be better understood in order to facilitate proper use of fosfomycin in salvage therapy. </p><p><br></p><p>The Subcommittee considered that fosfomycin could have a synergistic treatment effect when used with other agents and that the best use of fosfomycin may be against CRE, however, more evidence is needed to understand the agent and its optimal use. </p><p><br></p><p>The Subcommittee considered there were concerns about the rate of development of resistance to fosfomycin, seen in pre-clinical data and in real world clinical practice. </p><p><br></p><p>The Subcommittee considered that the clinical data for fosfomycin for the treatment of CRE infections is very limited and consists of very small case series, and the Subcommittee considered that is evidence base insufficient to assess the potential risks and benefits of fosfomycin for this indication. </p><p><br></p><p>The Subcommittee considered that further clinical trial data would be forthcoming for fosfomycin in the treatment of CRE infection. The Subcommittee considered that it would welcome a new funding application including further clinical trial data supporting the use of fosfomycin for this indication, once published.).</p>', 'Status_History__c': 'a132P000000B42qQAC'}, 'change': None}, {'Summary': {'s': '<p>This application is on holding pending more data supporting the use of fosfomycin in this indication.</p>', 'fs': '<p>This application is on holding pending more data supporting the use of fosfomycin in this indication.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Seeking further information.', 'fs': 'Seeking further information.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSF2A1'}, 'Id': 'a0POZ00000FSpSF2A1', 'Event_Date__c': '2019-05-31', 'Event_Description__c': 'Seeking further information.', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': '<p>This application is on holding pending more data supporting the use of fosfomycin in this indication.</p>', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000EDcfQAG'}, 'change': None}]",Jan 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2023', 'fs': 'Oct 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSG2A1'}, 'Id': 'a0POZ00000FSpSG2A1', 'Event_Date__c': '2023-10-05', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Oct 2023', 'Status_History__c': 'a13OZ000002VbyDYAS'}, 'change': None}]",Oct 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2023', 'fs': 'Oct 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSH2A1'}, 'Id': 'a0POZ00000FSpSH2A1', 'Event_Date__c': '2023-10-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Oct 2023', 'Status_History__c': 'a13OZ000002VfsaYAC'}, 'change': None}]",Oct 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSI2A1'}, 'Id': 'a0POZ00000FSpSI2A1', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FTYLsYAP'}, 'change': None}]",Oct 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSpSJ2A1'}, 'Id': 'a0POZ00000FSpSJ2A1', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCluNYAT'}, 'change': None}]",Nov 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
